Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE
This study is currently recruiting participants.
Study NCT00461630 Information provided by University of Oxford
First Received: April 17, 2007 Last Updated: November 4, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cardiovascular Disease
Peripheral Arterial Disease
Diabetes Mellitus
Coronary Heart Disease
Additional conditions recognized in this trial
Cardiovascular Diseases
Coronary Artery Disease
Coronary Disease
Heart Diseases
Peripheral Vascular Diseases
More general conditions related to this trial
Arterial Occlusive Diseases
Arteriosclerosis
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Myocardial Ischemia
Vascular Diseases
Interventions listed in this trial
ER niacin/laropiprant
simvastatin
ezetimibe
Additional drug interventions recognized in this trial
Niacin
More general drug interventions related to this trial
Anticholesteremic Agents
Antilipemic Agents
Antimetabolites
Cardiovascular Agents
Enzyme Inhibitors
Growth Substances
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vasodilator Agents
Vitamin B Complex
Vitamins
Sponsors listed in this trial
University of Oxford
Merck
Back to top of Main Content
